Ocumension Therapeutics (HKG:1477)
Hong Kong · Delayed Price · Currency is HKD 5.33
-0.19 (-3.35%)
Sep 11, 2026, 4:08 PM HKT
Ocumension Therapeutics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 934.03 | 804.35 | 417.31 | 246.37 | 158.96 | 56.15 | |
Revenue Growth | 71.79% | 92.75% | 69.38% | 54.99% | 183.11% | 328.73% |
Cost of Revenue | 493.25 | 443.43 | 192.24 | 102 | 56.04 | 19.21 |
Gross Profit | 440.78 | 360.92 | 225.07 | 144.37 | 102.92 | 36.94 |
Selling, General & Admin | 494.69 | 445.39 | 416.91 | 422.4 | 373.79 | 253.81 |
Research & Development | 68.89 | 75.08 | 113.94 | 123.77 | 184.31 | 169.06 |
Operating Expenses | 564.75 | 521.13 | 531.5 | 546.51 | 558.78 | 422.86 |
Operating Income | -123.97 | -160.2 | -306.43 | -402.15 | -455.86 | -385.93 |
Interest Expense | -4.48 | -2.45 | -2.16 | -1.33 | -1.79 | -0.57 |
Interest & Investment Income | 3.58 | 6.4 | 22.22 | 21.92 | 28.22 | 26.89 |
Earnings From Equity Investments | - | - | - | - | - | -13.33 |
Currency Exchange Gain (Loss) | -0.49 | -2.9 | 1.92 | 1.1 | 22.42 | -13.37 |
Other Non Operating Income (Expenses) | -3.39 | -2.58 | 17.52 | -3.36 | 7.31 | 0.54 |
EBT Excluding Unusual Items | -128.75 | -161.74 | -266.94 | -383.81 | -399.71 | -385.77 |
Gain (Loss) on Sale of Investments | 3.96 | 3.27 | -0.32 | 1.16 | 1.25 | 99.84 |
Asset Writedown | - | - | - | 3.18 | -3.18 | - |
Other Unusual Items | - | - | - | - | -0.6 | 25.94 |
Pretax Income | -124.79 | -158.47 | -267.26 | -379.48 | -402.23 | -259.99 |
Income Tax Expense | 0.73 | 0.35 | 1.02 | 0.31 | 0.41 | - |
Earnings From Continuing Operations | -125.52 | -158.82 | -268.27 | -379.79 | -402.64 | -259.99 |
Net Income | -125.52 | -158.82 | -268.27 | -379.79 | -402.64 | -259.99 |
Net Income to Common | -125.52 | -158.82 | -268.27 | -379.79 | -402.64 | -259.99 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 815 | 791 | 684 | 649 | 633 | 607 |
Shares Outstanding (Diluted) | 815 | 791 | 684 | 649 | 633 | 607 |
Shares Change | 8.78% | 15.71% | 5.33% | 2.63% | 4.18% | 100.81% |
EPS (Basic) | -0.15 | -0.20 | -0.39 | -0.59 | -0.64 | -0.43 |
EPS (Diluted) | -0.15 | -0.20 | -0.39 | -0.59 | -0.64 | -0.43 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -134.17 | -225.92 | -258.84 | -316.47 | -392.22 |
Free Cash Flow Per Share | - | -0.17 | -0.33 | -0.40 | -0.50 | -0.65 |
Gross Margin | 47.19% | 44.87% | 53.93% | 58.60% | 64.74% | 65.78% |
Operating Margin | -13.27% | -19.92% | -73.43% | -163.23% | -286.78% | -687.36% |
Profit Margin | -13.44% | -19.74% | -64.29% | -154.16% | -253.30% | -463.06% |
Free Cash Flow Margin | - | -16.68% | -54.14% | -105.06% | -199.09% | -698.57% |
EBITDA | 6.43 | -29.95 | -232.31 | -355.76 | -428.76 | -376.31 |
EBITDA Margin | 0.69% | -3.72% | -55.67% | -144.40% | -269.74% | - |
D&A For EBITDA | 130.39 | 130.25 | 74.12 | 46.39 | 27.1 | 9.62 |
EBIT | -123.97 | -160.2 | -306.43 | -402.15 | -455.86 | -385.93 |
EBIT Margin | -13.27% | -19.92% | -73.43% | -163.23% | -286.78% | - |